Prognostic value and characterization of the ovarian cancer-specific antigen CA166-9

Ji,Fangxing; Chang,Xiaohong; Liu,Caiyun; Meng,Lin; Qu,Like; Wu,Jian; Liu,Chanzhen; Cui,Heng; Shou,Chengchao

doi:10.3892/ijo.2015.3115

Prognostic value and characterization of the ovarian cancer-specific antigen CA166-9

Authors:
- Fangxing Ji
- Xiaohong Chang
- Caiyun Liu
- Lin Meng
- Like Qu
- Jian Wu
- Chanzhen Liu
- Heng Cui
- Chengchao Shou
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Gynecological Oncology Center, Peking University People's Hospital, Beijing 100044, P.R. China
Published online on: August 6, 2015 https://doi.org/10.3892/ijo.2015.3115
Pages: 1405-1415

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

COC166-9 is an ovarian cancer-specific monoclonal antibody, and COC166-9-based immunotherapy has been shown to possess killing effects against ovarian cancer cells in vitro and in vivo. However the antigen recognized by COC166-9 (COC166-9-Ag, CA166-9) has not been identified and the clinical significance of CA166-9 expression remains unknown. We found that CA166-9 was positive in 53.1% of ovarian cancer tissues. Expression of CA166-9 was strongly correlated with the cancer recurrence (P<0.001). Patients with positive CA166-9 had substantially shorter overall survival (P=0.026) and disease-free survival (P=0.002). CA166-9 was also shown to be an independent predictive factor for overall survival (HR=2.454, P=0.016) and disease-free survival (HR=2.331, P=0.021). We identified CA166-9 as human immunoglobulin γ-1 heavy chain constant region (IGHG1). Purified IGHG1 promoted proliferation, migration, and invasion of CA166-9-negative ovarian cancer HOC1A cells, whereas it had minimal effects on the phenotypes of CA166-9-positive ovarian cancer CAOV-3 cells. In addition, overexpression of IGHG1 enhanced migration of ovarian cancer cells. On the contrary, COC166-9 inhibited proliferation, migration, and invasion of CAOV-3 cells, but had no effects on HOC1A cells. Therefore, IGHG1 similarly to CA166-9, could play an important role in ovarian cancer development and may serve as a potential prognostic marker and a therapeutical target for ovarian cancer.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Memarzadeh S, Lee SB, Berek JS and Farias-Eisner R: CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 13:120–124. 2003. View Article : Google Scholar : PubMed/NCBI
3	Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z and Mills GB: CA 125: The past and the future. Int J Biol Markers. 13:179–187. 1998.
4	Bast RC Jr, Skates S, Lokshin A and Moore RG: Differential diagnosis of a pelvic mass: Improved algorithms and novel biomarkers. Int J Gynecol Cancer. 22(Suppl 1): S5–S8. 2012. View Article : Google Scholar : PubMed/NCBI
5	Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE and Goff BA: Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 204:466–478. 2011. View Article : Google Scholar : PubMed/NCBI
6	Qian HN, Feng J, Cui H, Fu TY, Wei P and Fu ZY: Generation and characterization of three monoclonal antibodies to human ovarian epithelial adenocarcinomas. Chin Med J (Engl). 102:839–843. 1989.
7	Qian HN: Immunohistological analysis of monoclonal antibody COC166-9 against primary ovarian epithelial cancer. Zhonghua Bing Li Xue Za Zhi. 17:207–209. 1988.(In Chinese). PubMed/NCBI
8	Qian HN and Li WJ: Target therapy of ovarian carcinoma by monoclonal antibodies bearing chemical drugs entrapped in liposomes. Chin Med J (Engl). 106:343–347. 1993.
9	Li X, Qian H and Feng J: Preparation of F(ab′)2 fragment of monoclonal antibody COC166-9 and its experimental study of radioimmunoimaging for ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi. 32:152–155. 1997.(In Chinese). PubMed/NCBI
10	Chang X, Cui H, Feng J, Li Y, Liu B, Cao S, Cheng Y and Qian H: Preparation of humanized ovarian carcinoma anti-idiotypic minibody. Hybrid Hybridomics. 22:109–115. 2003. View Article : Google Scholar : PubMed/NCBI
11	Feng J, Lü J and Qian H: Serological analysis of antibodies by anti-idiotypic monoclonal antibody 6B11 against ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi. 31:493–495. 1996.(In Chinese). PubMed/NCBI
12	Cui H, Chang XH, Liu B, Feng J, Li Y, Ye X, Cao SJ, Fu TY, Yao Y, Li HQ, et al: The anti-tumor immune responses induced by a fusion protein of ovarian carcinoma anti-idiotypic antibody 6B11ScFv and murine GM-CSF in BALB/c mice. Int J Gynecol Cancer. 14:234–241. 2004. View Article : Google Scholar : PubMed/NCBI
13	Shi J, Chang X, Feng J, Cheng Y, Cheng H, Guo H, Ye X and Cui H: Expression of an ovarian cancer anti-idiotype antibody (6B11VLVHCH3) in Chinese hamster ovary (CHO) cells with improved immunoactivity and stability over proteins expressed in prokaryotic cells. Hybridoma (Larchmt). 26:289–295. 2007. View Article : Google Scholar
14	Yang W, Feng J, Chang X, Fu T, Ye X, Zhang H, Li X, Wen H, Feng L, Tong C, et al: Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells. Gynecol Oncol. 105:238–243. 2007. View Article : Google Scholar : PubMed/NCBI
15	Li W, Cui H, Meng FQ, Chang XH, Zhang G, Liu B and Li ZH: New T cell epitopes identified from an anti-idiotypic antibody mimicking ovarian cancer associated antigen. Cancer Immunol Immunother. 57:143–154. 2008. View Article : Google Scholar
16	Stone GC, Sjöbring U, Björck L, Sjöquist J, Barber CV and Nardella FA: The Fc binding site for streptococcal protein G is in the C gamma 2-C gamma 3 interface region of IgG and is related to the sites that bind staphylococcal protein A and human rheumatoid factors. J Immunol. 143:565–570. 1989.PubMed/NCBI
17	Kimoto Y: Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes Chromosomes Cancer. 22:83–86. 1998. View Article : Google Scholar : PubMed/NCBI
18	Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61:2129–2137. 2001.PubMed/NCBI
19	Li J, Tan C, Xiang Q, Zhang X, Ma J, Wang JR, Yang J, Li W, Shen SR, Liang S, et al: Proteomic detection of changes in protein synthesis induced by NGX6 transfected in human nasopharyngeal carcinoma cells. J Protein Chem. 20:265–271. 2001. View Article : Google Scholar : PubMed/NCBI
20	Qiu X, Zhu X, Zhang L, Mao Y, Zhang J, Hao P, Li G, Lv P, Li Z, Sun X, et al: Human epithelial cancers secrete immunoglobulin G with unidentified specificity to promote growth and survival of tumor cells. Cancer Res. 63:6488–6495. 2003.PubMed/NCBI
21	Babbage G, Ottensmeier CH, Blaydes J, Stevenson FK and Sahota SS: Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer Res. 66:3996–4000. 2006. View Article : Google Scholar : PubMed/NCBI
22	Ma C, Wang Y, Zhang G, Chen Z, Qiu Y, Li J, Luo J, Huang B, Jiang C, Huang G, et al: Immunoglobulin G expression and its potential role in primary and metastatic breast cancers. Curr Mol Med. 13:429–437. 2013.PubMed/NCBI
23	Niu N, Zhang J, Huang T, Sun Y, Chen Z, Yi W, Korteweg C, Wang J and Gu J: IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLoS One. 7:e473622012. View Article : Google Scholar : PubMed/NCBI
24	Liu Y, Chen Z, Niu N, Chang Q, Deng R, Korteweg C and Gu J: IgG gene expression and its possible significance in prostate cancers. Prostate. 72:690–701. 2012. View Article : Google Scholar : PubMed/NCBI
25	Chen Z, Huang X, Ye J, Pan P, Cao Q, Yang B, Li Z, Su M, Huang C and Gu J: Immunoglobulin G is present in a wide variety of soft tissue tumors and correlates well with proliferation markers and tumor grades. Cancer. 116:1953–1963. 2010. View Article : Google Scholar : PubMed/NCBI
26	Li M, Zheng H, Duan Z, Liu H, Hu D, Bode A, Dong Z and Cao Y: Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. Cell Mol Immunol. 9:54–61. 2012. View Article : Google Scholar
27	Manson LA: Anti-tumor immune responses of the tumor-bearing host: The case for antibody-mediated immunologic enhancement. Clin Immunol Immunopathol. 72:1–8. 1994. View Article : Google Scholar : PubMed/NCBI
28	Hellström I, Hellström KE, Evans CA, Heppner GH, Pierce GE and Yang JP: Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci USA. 62:362–368. 1969. View Article : Google Scholar : PubMed/NCBI